Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
29 septembra, 2020 8:29 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4003 Citation: J Clin Oncol 35,...
Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
29 septembra, 2020 8:29 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4001 Citation: J Clin Oncol 35,...
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
29 septembra, 2020 8:29 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3505 Citation: J Clin Oncol 35,...
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)
29 septembra, 2020 8:29 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3503 Citation: J Clin Oncol 35,...
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
29 septembra, 2020 8:29 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: LBA1 Citation: J Clin Oncol 35,...
Risk-Based Approach to Chemotherapy Duration Recommended for Stage III Colon Cancer
29 septembra, 2020 8:29 pmJune 4, 2017 effective as a standard 6-month course—with a difference in disease-free survival (DFS) of less than 1%—while...
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study
29 septembra, 2020 8:29 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4006 Citation: J Clin Oncol 35,...
Post-Surgery Capecitabine ‘Should Become Standard of Care’ in Biliary Tract Cancers
29 septembra, 2020 8:29 pmJune 4, 2017 In a study of 447 patients with biliary tract cancers, capecitabine improved overall survival (OS) when...
Najvýznamnejšie klinické správy z konferencie ASCO 2017 v problematike nádorov gastrointestinálneho traktu
29 septembra, 2020 8:29 pmPočas prvého júnového týždňa tohto roka sa konal v Chicagu tradičný výročný kongres Americkej onkologickej spoločnosti (ASCO). Ako obvykle v rámci prednášok...
Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer – Metastatic Abstract number: 1005 Authors: Guy Heinrich Maria...